Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
|
31416841 |
2019 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Survival analysis further revealed that high expression of BCL2L1 corresponded to reduced survival of lung cancer patients (HR (95%CI) = 1.75(1.33~2.30)), while patient survival time was unaffected by expression of IGF1R (HR (95%CI) = 1.15 (0.98~1.36)).
|
30497474 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knockdown of TESC suppressed CSC-like properties as well as STAT3 activation through inhibition of insulin-like growth factor 1 receptor (IGF1R), a major signaling pathway of lung cancer stem cells.
|
30013043 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we carried out a comparative gene expression analysis to generate a detailed molecular portrait of a transgenic mouse model of IGFIR-driven lung cancer.
|
30412601 |
2018 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Co-delivery of insulin-like growth factor 1 receptor specific siRNA and doxorubicin using chitosan-based nanoparticles enhanced anticancer efficacy in A549 lung cancer cell line.
|
28362176 |
2018 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore they indicate that nuclear expression of IGF1R contributes to EGFR-TKI resistance in lung cancer.
|
29421153 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the current study, four major overexpressed RTKs - EGFR, FGFR1, IGF1R and c-Met - involved in human lung cancer were investigated.
|
29022361 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further understanding of the signaling pathways and a biomarker that can predict efficacy is needed prior to further clinical development of IGF-1R inhibitors in lung cancer.
|
27686971 |
2017 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The insulin-like growth factor-1 receptor (IGF-1R) is a central component of lung cancer signal transduction pathways.
|
28104361 |
2017 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that blocking β-AR-mediated IGF-1R activation can be an effective strategy for lung cancer prevention in smokers.
|
27708216 |
2016 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, these finding suggest that IGF1R inhibition or combination of EGFR-IGF1R inhibition strategies would be potential ways to prevent or potentiate the effects of current therapeutic options to lung cancer patients demonstrating resistance to either first or second generation EGFR TKIs.
|
26052929 |
2016 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to investigate the prognostic role of IGF-1R expression in surgically resected non-small-cell lung cancer (NSCLC), and responses to IGF-1R tyrosine kinase inhibitor NVP-ADW742 in a panel of lung cancer cell lines.
|
25081930 |
2015 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, the expression and clinical significance of IGF1R were investigated in serum and lung cancer tissues from small cell lung cancinoma (SCLC).
|
26430715 |
2015 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MiR-133a can inhibit cell invasiveness and cell growth through suppressing the expressions of IGF-1R, TGFBR1 and EGFR, which then influences the downstream signaling in lung cancer cell lines.
|
24816813 |
2014 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In work arising from the clinical observation of a patient with ALK fusion-positive lung cancer who had an exceptional response to an insulin-like growth factor 1 receptor (IGF-1R)-specific antibody, we define a therapeutic synergism between ALK and IGF-1R inhibitors.
|
25173427 |
2014 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.
|
24458568 |
2014 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.
|
24489728 |
2014 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combining IGF1R and MAP-ERK kinase blockade led to significant effects on viability in human non-small cell lung cancer (NSCLC) cell lines and in 2 mouse models of oncogenic KRAS-driven lung cancer.
|
23658296 |
2013 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The combined treatment of vorinostat and ad-sh-IGF-1R appears to have promising potential as a new therapeutic approach for lung cancer.
|
23413016 |
2013 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
This work sheds light on the ability of RASto activate PI3K through direct interaction, indicating that input is also required from a receptor tyrosinekinase, IGF1R in the case of KRAS -mutant lung cancer.
|
23454899 |
2013 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.
|
22359227 |
2012 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Computational model of EGFR and IGF1R pathways in lung cancer: a Systems Biology approach for Translational Oncology.
|
21620944 |
2012 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study evaluates the IGF1R expression in regard to outcomes and molecular markers of EGFR activity in lung cancer patients treated with gefitinib.
|
22593449 |
2012 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, recent clinical trials showed that anti-IGF1R antibody and chemotherapy are not effective for treating lung cancer.
|
22438913 |
2012 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Suppression of IGF1R gene expression by shRNA enhances the chemosensitivity of A549 cells to DDP both in vitro and in vivo, indicating the therapeutic potential of RNA interference as a method for gene therapy in treating lung cancer.
|
18535748 |
2008 |